"The pathogen c.diff recurs in approximately 25% of patients within two months," says Georg Gerber, PhD, Brigham and Women's Hospital. In this podcast, Gerber reflects on the impact funding received from Harvard Catalyst has had on his research which focuses on recurring infections.

Transcript: https://bit.ly/3pkMI2K

"The pathogen c.diff recurs in approximately 25% of patients within two months," says Georg Gerber, PhD, Brigham and Women's Hospital. In this podcast, Gerber reflects on the impact funding received from Harvard Catalyst has had on his research which focuses on recurring infections. Transcript: https://bit.ly/3pkMI2K

Share Translational Innovator: The Science Behind Recurring C. Difficile Infections

Sign up to save your podcasts

Translational Innovator: The Science Behind Recurring C. Difficile Infections

Translational Innovator: The Science Behind Recurring C. Difficile Infections